Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathological features and endoscopic findings of HER2-positive gastric cancer

(2018) Yasuhiro Oono et al.   SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models

(2018) Masakazu Yashiro et al.   Human Cell

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

(2017) Hideo Saka et al.   INVESTIGATIONAL NEW DRUGS

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

(2017) Michael Michael et al.   Targeted Oncology

CXCL1–Chemokine (C-X-C Motif) Receptor 2 Signaling Stimulates the Recruitment of Bone Marrow–Derived Mesenchymal Cells into Diffuse-Type Gastric Cancer Stroma

(2016) Hiroaki Kasashima et al.   AMERICAN JOURNAL OF PATHOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity

(2015) Camillo Porta et al.   Future Oncology

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

(2014) Y J Liu et al.   BRITISH JOURNAL OF CANCER

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

(2014) Paulina Grygielewicz et al.   Gastric Cancer

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

(2013) E. Angevin et al.   CLINICAL CANCER RESEARCH

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

(2013) L. Xie et al.   CLINICAL CANCER RESEARCH

FGF Receptors: Cancer Biology and Therapeutics

(2013) Masaru Katoh et al.   MEDICINAL RESEARCH REVIEWS

FGFR2 gene amplification and clinicopathological features in gastric cancer

(2012) K Matsumoto et al.   BRITISH JOURNAL OF CANCER

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

(2012) P. R. Gavine et al.   CANCER RESEARCH

Cancer-associated orthotopic myofibroblasts stimulates the motility of gastric carcinoma cells

(2012) Yuhiko Fuyuhiro et al.   CANCER SCIENCE

Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer

(2012) A. N. Brooks et al.   CLINICAL CANCER RESEARCH

Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry

(2012) Atsushi Nashimoto et al.   Gastric Cancer

Match criteria for human cell line authentication: Where do we draw the line?

(2012) Amanda Capes-Davis et al.   INTERNATIONAL JOURNAL OF CANCER

Borrmann’s Macroscopic Criteria and p-Smad2 Expression Are Useful Predictive Prognostic Markers for Cytology-Positive Gastric Cancer Patients Without Overt Peritoneal Metastasis

(2011) Satoru Noda et al.   ANNALS OF SURGICAL ONCOLOGY

Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells

(2011) Y Fuyuhiro et al.   BRITISH JOURNAL OF CANCER

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Myofibroblasts are associated with the progression of scirrhous gastric carcinoma

(2010) YUHIKO FUYUHIRO et al.   Experimental and Therapeutic Medicine

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

(2008) K. Kunii et al.   CANCER RESEARCH